Bromopium Injection (Simephtropium Bromide)

Adult administration

(Tablets) Adults: Administer cimetropium bromide 50 mg per dose 2 ∼ 3 times daily. (Injection) 1. Gastrointestinal spasms accompanied by irritable bowel pain: Inject cimetropium bromide 5 mg per dose intramuscularly or intravenously. 2. Premedication before examination: Administer 10 mg per dose of this drug by intravenous injection over at least 40 minutes.

This medication is a glass ampule injectable, so there is a risk of glass fragments mixing in when cutting the container, potentially causing side effects. Therefore, care must be taken to minimize glass particles when cutting, particularly when administering to children or the elderly. Patients with hypersensitivity to the main ingredient or any other components, patients with benign prostatic hyperplasia, glaucoma, urinary retention, functional obstruction of the gastrointestinal tract, paralytic ileus, ulcerative colitis, megacolon, gastroesophageal reflux disease, myasthenia gravis should not be administered this medication. Caution should be exercised when administering to patients with autonomic nervous system diseases, liver and kidney diseases, chronic obstructive pulmonary disease, hyperthyroidism, coronary artery disease, congestive heart failure, arrhythmia, hypertension, and paradoxical heat response. In particular, when administering the injection, it is essential to confirm whether abdominal pain is due to myocardial infarction. This medication may cause temporary dry mouth, and in the case of high doses, symptoms such as difficulty focusing, rapid heartbeat, and sensory disturbances may occur. Difficulty urinating, increased intraocular pressure, headaches, dizziness, facial flushing, drowsiness, weakness, constipation, nausea, and allergic skin reactions may also occur. This medication may cause drowsiness, so patients should avoid driving or operating dangerous machinery while taking it. Since the injection contains sodium, patients who need to pay attention to sodium intake should consider this. Concurrent use with other antihistamines, phenothiazine drugs, tricyclic antidepressants, and anticholinergic drugs may enhance the anticholinergic effects of this medication, so it is advisable not to combine them. Additionally, sympathomimetic agents can diminish or negate the effectiveness of this drug. Pregnant women or women who may become pregnant should use this medication with caution, as its safety has not been established, and it should only be given when the therapeutic benefits outweigh the risks. The safety of this medication in children has not been established, and special care should be taken when using anticholinergic drugs in infants, as central nervous system excitation symptoms or respiratory obstruction symptoms may occur. Seizures may occur with high-dose administration, and there is a potential for habit formation and dependency, so caution is advised. In case of overdose, urgent intervention with the specific antidote, physostigmine salicylate, should be administered intramuscularly, and treatment according to symptoms is necessary. This medication should be kept out of reach of children, and transferring it to another container is not recommended for quality maintenance and safety reasons.

• dry mouth
• accommodation disorder
• palpitations
• sensory disturbances
• dysuria
• increased intraocular pressure
• headache
• dizziness
• facial flushing
• dysphoria

This medication should be stored in a sealed container to protect it from air and moisture and should be kept at a temperature between 1 and 30 degrees Celsius for safety. Proper storage will help maintain the drug's effectiveness for a longer period.

Appearance

A colorless, transparent liquid contained in a brown ampule.

Package unit

1 ampule (1 milliliter) × 50 ampules, 1 ampule (2 milligrams) × 50 ampules